Liver Cirrhosis, Biliary Clinical Trial
Official title:
An Open-Label, Dose-Finding Study for the CBP / β-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
To evaluate the safety and pharmacokinetics of OP-724 and to determine the recommended dose of OP-724 against Primary Biliary Cholangitis patients.
This trial is a phase I trial aimed at examining the safety and tolerability of OP-724 in patients with primary biliary cholangitis and determining the recommended dose. The subjects are patients diagnosed with primary biliary cholangitis and diagnosed as progress of fibrosis (Scheuer stage III or higher) as a result of liver tissue examination. As a dosing schedule, OP-724 is intravenously administered twice a week (4 hours) for 12 weeks. However, once 7 days prior to the first cycle of administration, a dose scheduled for the first cycle will be administered once by continuous intravenous administration for 4 hours, and safety and pharmacokinetics will be evaluated on the day of administration to the next day after administration. The dose level shall be 3 doses (140 mg/m2/4hrs, 280 mg/m2/4hrs [starting dose], 380 mg/m2/4hrs), of which 2 doses shall be registered for up to 6 patients each. The safety and pharmacokinetic data after OP-724 administration will be decided comprehensively to determine the recommended dose in the next phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
| Terminated |
NCT00550862 -
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
|
Phase 2 | |
| Completed |
NCT00004748 -
Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
|
Phase 3 | |
| Completed |
NCT03630718 -
Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women
|
N/A | |
| Completed |
NCT00004842 -
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
|
Phase 1 | |
| Terminated |
NCT03633227 -
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
|
Phase 4 | |
| Terminated |
NCT00125281 -
SAMe to Treat Biliary Cirrhosis Symptoms
|
Phase 2 | |
| Completed |
NCT04629456 -
Physical Therapy for Liver Cirrhosis
|
N/A | |
| Recruiting |
NCT03468699 -
Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
|
Phase 2 | |
| Completed |
NCT00004784 -
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
|
Phase 3 | |
| Completed |
NCT00006168 -
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
|
Phase 3 | |
| Completed |
NCT00570765 -
Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
|
Phase 2 | |
| Recruiting |
NCT00160940 -
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis
|
N/A | |
| Recruiting |
NCT03146910 -
Swiss Primary Biliary Cholangitis Cohort Study
|
||
| Terminated |
NCT03265249 -
BRIDGE Device for Post-operative Pain Control
|
N/A | |
| Terminated |
NCT02308111 -
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
|
Phase 4 | |
| Recruiting |
NCT02936596 -
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
|
N/A | |
| Completed |
NCT00406237 -
Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
|
Phase 1 | |
| Recruiting |
NCT00145964 -
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)
|
N/A | |
| Terminated |
NCT03476993 -
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis
|
Phase 2 |